OPKO Health and Entera Bio, a leader in the development of oral peptides and protein replacement therapies, entered into a ...

Delpharm, a CDMO, has reached an agreement with the Government of Canada to modernize its injectable manufacturing facility in Boucherville.

Huyabio International has appointed Paul Spreen as Chief Business Officer. “We are delighted to welcome Paul Spreen to the HUYA executive team,” said Dr. Mireille Gillings, President, CEO & Executive ...

Kincell Bio, a cell therapy developer and manufacturer, has appointed Larry Pitcher as Chief Operating Officer (COO).

Araris is advancing three preclinical candidates for the treatment of hematological and solid tumors developed using its ...

To leverage Alteogen's ALT-B4 Hybrozyme platform technology for large volume subcutaneous administration of drugs.

Oncologi, Inc., a clinical-stage biopharmaceutical company, announced the acquisition of TargImmune Therapeutics, a biotechnology company specializing in novel tumor-targeted imm ...

Funds will help the companies create a platform for the manufacturing and characterization of AAV-based gene therapy vectors.

Curia will expand its Glasgow, UK facility and offers updates on the ongoing expansion to its Albuquerque, NM facility.

Humanetics Corporation, a clinical-stage pharmaceutical company, has selected Lifecore Biomedical, a fully integrated CDMO, ...

HightByte’s PAS-X MES will integrate as part of the Körber Ecosystem Partner Program for improved data visibility and ...

C2N Diagnostics, LLC, a specialty diagnostics company, has received a $10 million investment from Samsung C&T Corporation, Samsung Biologics, Samsung Bioepis, and Samsung Venture Investment ...